ABSTRACT
Objective To observe the influence of edaravin combined with cerebroside-kinin on the level of glial fiber acidic protein (GFAP) and ubiquitin carboxyl terminal-L1 (UCH-L1) in the treatment of severe craniocerebral injury.Methods From January 2016 to December 2017,a total of 123 patients with severe craniocerebral injury were selected in our hospital,and randomly(random number) assigned to the observation group (61 cases) and control group (62 cases).Patients in the control group were given cerebroside-kinin,and patients in the observation group were given cerebroside-kinin and edaravone.The acute physiology and chronic health evaluation score (APACHE Ⅱ),activities of daily living (ADL) score,serum malonaldehyde (MDA),superoxide dismutase (SOD),myeloperoxidase (MPO),matrix metalloprotein 9 (MMP-9),GFAP and UCH-L1 before and after treatment were observed.The side effects were also recorded.Results The APACHE Ⅱ score was significantly reduced in both groups after treatment (P=0.008;P=0.003),and was lower in the observation group than that in the control group (P=0.013).The ADL score of both groups increased after treatment (P=0.025;P=0.008),and was higher in the observation group than that in the control group (P=0.012).After treatment the levels of MDA,SOD and MPO in the observation group were significantly higher than those in the control group (P＜0.05);the level of MMP-9 in the observation group was significantly lower than that in the control group (P=0.012);the levels of GFAP and UCH-L 1 in the observation group were significantly higher than those in the control group (P=0.014;P=0.035).There was no significant difference of the total side effect incidence between the observation group and the control group (8.06％ vs 9.83％,x 2=0.088,P=0.719).Conclusions The treatment by edaravone combined with cerebroside-kinin on severe craniocerebral injury may effectively protect the nerve cells,improve nerve function,clinical efficacy and the body's antioxidant capacity,reduce the serum levels of GFAP,UCH-L1,and have better safety.
ABSTRACT
Objective To make clear glial acidic protein and excitatory amino acid levels in the early expression of neonatal brain injury and the mechanism of brain injury,and the value of early diagnosis and prediction of serum glial fiber acidic protein and excitatory amino acid in neonatal cerebral palsy.Methods This study chose high-risk infants with cerebral palsy as the research object,the concentration of excitatory amino acid and enzyme linked immunosorbent assay were detected by reverse phase high performance liquid chromatography,followed up for 12 months,the occurrence of cerebral palsy was analyzed statistically.Results Compared with the normal group of glial fibrillary acidic protein,glutamic acid and aspartic acid levels,three indexes of children with cerebral palsy were higher than normal group(glial fibrillary acidic protein:(119.46±43.68),(119.46±43.68),(62.57±35.31),(134.02±32.79) ng/L;glutamic acid:(7.52±3.94),(6.49±2.88),(8.15 ±2.03),(1.72±0.59) μmol/L;aspartic acid:(3.81±1.09),(4.23±1.91),(3.67±2.14),(1.35±0.71) μmol/L;F=4.117,4.117,4.117;P0.05).The levels of serum glial fiber acidic protein,glutamic acid and aspartate in children with cerebral palsy were higher than those in the normal group,comparison between spastic group,athetotic group and mixed group(F=5.032,6.004,3.792),there was no significant difference in the levels of glial acidic protein,glutamic acid and aspartate(P>0.05).Conclusion The concentration of excitatory amino acids and acidic protein in the serum of the patients with high risk of cerebral palsy has some value,the concentration of serum excitatory amino acid and the concentration of glial fiber acidic protein are correlated with the degree of brain injury and the time in children with cerebral palsy.
ABSTRACT
OBJECTIVE:To investigate the effects of TanshinoneⅡA sodium sulfonate injection on levels of P-selectin,glial fi-brillary acidic protein (GFAP),vascular endothelial growth factor (VEGF) and neurological function in patients with acute cere-bral infarction. METHODS:A total of 114 patients with acute cerebral infarction selected from Lianyungang First People's Hospi-tal during Apr. 2013-Apr. 2016 were divided into control group and observation group according to random number table,with 57 cases in each group. Control group was given routine treatment. Observation group was additionally given Tanshinone ⅡA sodium sulfonate injection 40 mg 0.9％ sodium chlonride injection 250 mL,ivgtt,qd. A treatment course lasted for 7 d,and both received 2 courses of treatment. NIHSS scores,the levels of serum P-selectin,GFAP and VEGF were compared between 2 groups before treatment and after 7,14 d of treatment. The occurrence of ADR was also compared. RESULTS:Before treatment,there was no statistical significance in above indexes between 2 groups(P>0.05). Compared to before treatment,NIHSS score,the levels of se-rum P-selectin and GFAP in 2 groups were decreased significantly after 7,14 d of treatment,while the serum level of VEGF was increased significantly. These indexes of 2 groups after 14 d of treatment were significantly better than 7 d of treatment,except for NIHSS score. Above indexes of observation group was significantly better than those of control group during corresponding period, with statistical significance (P<0.05). No obvious ADR was found in 2 groups. CONCLUSIONS:For acute cerebral infarction, Tanshinone ⅡA sodium sulfonate injection can significantly reduce the levels of serum P-selectin and GFAP,improve VEGF level and promote the recovery of neurological damage with good safety.